AstraZeneca picks up a friend for Tagrisso in $40M upfront deal

02 Jan 2024
·
Deals
www.fiercebiotech.com
Drug ApprovalLicense out/in
AstraZeneca picks up a friend for Tagrisso in $40M upfront deal
Preview
Source: FierceBiotech
Allorion’s EGFR inhibitorEGFR inhibitor could enhance the activity of existing medicines through combination regimens—including AstraZeneca's Tagrisso.
AstraZeneca is tossing a little cash towards Allorion Therapeutics to pick up a friend for approved lung cancer med Tagrisso.
The deal includes upfront and near-term milestones of $40 million, with development and commercial milestones of $500 million total possible, plus royalties, according to a Tuesday press release.
Small molecule biotech Allorion will pass a novel EGFR L858R allosteric inhibitorEGFR L858R allosteric inhibitor over to the Big Pharma to develop and commercialize globally in advanced EGFR-mutant non-small cell lung cancer (NSCLC).
The program will fit in nicely with AstraZeneca’s EGFR inhibitorEGFR inhibitor Tagrisso, which is already approved for NSCLC after tumor resection with curative intent. While Tagrisso has been a leader in the indication for several years, questions have begun to percolate about its future, as the therapy missed analyst consensus on sales by 2% in the third quarter and declined sequentially.
Tagrisso combined with chemotherapy recently showed impressive benefits in staving off tumor progression compared with the therapy alone in newly diagnosed, metastatic EGFR-mutant NSCLC in the late-stage FLAURA2 trial. Experts wanted to see an overall survival advantage, but data there are still immature.
Allorion’s EGFR inhibitorEGFR inhibitor is designed to address mechanisms of resistance to current therapies, Chief Scientific Officer Fang Li, PhD., said in Tuesday’s release. The therapy could also enhance the activity of existing medicines through combination regimens—including Tagrisso, he noted.
The biotech, which has headquarters in both Natick, Massachusetts and Guangzhou, China, has five programs in the works in cancer and autoimmune disease. The most advanced are in phase 1/2 development: ARTS-011 targeting TYK2 and ARTS-021 for CDK2.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.